S&P Biotech SPDR (XBI)
$94.87 0.16 (0.17%)
11:52 EST XBI Stock Quote Delayed 15 Minutes
Previous Close $94.71
Market Cap 5.13B
PE Ratio -
Volume (Avg. Vol.) 1.50M
Day's Range 94.71 - 95.62
52-Week Range 72.97 - 98.79
Dividend & Yield 0.23 (0.24%)
XBI Stock Predictions, Articles, and S&P Biotech SPDR News
- From InvestorPlace
- From the Web
By Ian Cooper
Some of the biggest catalysts for future growth in drug stocks include the millions of retiring baby boomers, and new innovative treatments for a variety of medical issues.
Bitcoin, Biotech, Micron and Starbucks were our top stock trades to watch. Here's how the charts are setting up going into Friday.
HEXO stock is down 50% since the end of April. But inside this support zone, the bulls can mount a 20% rally if headlines cooperate.
SPDR ETFs span an array of asset classes, including stocks, bond, commodities and real estate, among others. Here are 7 of the best ETFs to buy from SPDR.
Memory stocks like Micron and semiconductor stocks like AMD were on the move in the Nasdaq today. Intel and Cisco weren't so lucky though.
This morning I am recommending a bearish trade on the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).
As the Best ETFs contest enters its final quarter, there are a few contenders that could reasonably take the trophy for 2018.
As our Best ETFs for 2018 contest crosses into the second half of the year, a few contestants are really making standout gains, but others are making strong moves.
The biotech sector peaked in 2015. While it bounced back from lows, biotech ETFs give investors exposure to the sector as it recovers.
A phase of weakness has hit Wall Street, but the dip could be a buy. Here are three bullish options trades to consider in V, BIDU and XBI.
Which funds are going to kick the competition to the curb this year? We have 10 experts who think they know the best ETFs for 2018.
XBI can profit from full drug pipelines, an improving regulatory climate, high short interest and strengthening technicals.
By Jeff Reeves
The best healthcare ETFs for 2018 offer growth and stability. These funds show healthcare investing is both low risk and high reward.
Biotech stocks are scary when they are falling. Sell downside risk into BIIB stock support with confidence for a chance at free profits.
For a while GILD stock was a hideous knife to catch. But now that it reestablished its bottom, I can safely make money in Gilead.
Pharma stocks like Allergan scare most investors out of trading them when they fall. Sell AGN puts with a big buffer for easy profits.